Literature DB >> 25374200

Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk.

Hua Xu1, Qiang Ding, Hao-Wen Jiang.   

Abstract

PURPOSE: We aimed to investigate the associations between polymorphisms of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer (PCa) risk.
MATERIALS AND METHODS: A comprehensive search for articles of MEDLINE and EMBASE databases and bibliographies of retrieved articles published up to August 3, 2014 was performed. Methodological quality assessment of the trials was based on a standard quality scoring system. The meta-analysis was performed using STATA 12.0.
RESULTS: We included 9 studies (1 study for IL-1A, 5 studies for IL-1B, and 3 studies for IL-1RN), and significant association was found between polymorphisms of IL-1B-511 (rs16944) as well as IL-1B-31 (rs1143627) and PCa risk. IL-1B-511 (rs16944) polymorphism was significantly associated with PCa risk in homozygote and recessive models, as well as allele contrast (TT vs CC: OR, 0.74; 95%CI, 0.58-0.94; P=0.012; TT vs TC+CC; OR, 0.79; 95%CI, 0.63-0.98; P=0.033; T vs C: OR, 0.86; 95%CI, 0.77-0.96; P=0.008). The association between IL-1B-31 (rs1143627) polymorphism and PCa risk was weakly significant under a heterozygote model (OR, 1.35; 95%CI, 1.00-1.80; P=0.047).
CONCLUSIONS: Sequence variants in IL-1B-511 (rs16944) and IL-1B-31 (rs1143627) are significantly associated with PCa risk, which provides additional novel evidence that proinflammatory cytokines and inflammation play an important role in the etiology of PCa.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25374200     DOI: 10.7314/apjcp.2014.15.20.8741

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis.

Authors:  Wencheng Li; Min Gu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice.

Authors:  Jimeng Hu; Tian Yang; Hua Xu; Mengbo Hu; Hui Wen; Haowen Jiang
Journal:  Int Urol Nephrol       Date:  2016-06-09       Impact factor: 2.370

4.  Interleukin 10 rs1800896 and interleukin 1B rs16944 polymorphisms and the risk of cervical cancer.

Authors:  Jasenka Wagner; Sanela Štibi; Nikica Selak; Ilija Alvir; Ivica Mamić; Luka Marcelić; Lucija Šušnjar; Mario Puljiz; Marija Heffer; Damir Danolić
Journal:  Wien Med Wochenschr       Date:  2022-01-18

5.  The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma.

Authors:  Xueyun Zhao; Mingqiang Hua; Shuxin Yan; Jie Yu; Fengjiao Han; Chaoqin Zhong; Ruiqing Wang; Chen Zhang; Ming Hou; Daoxin Ma
Journal:  J Immunol Res       Date:  2018-08-23       Impact factor: 4.818

6.  Association between IL1B gene and cervical cancer susceptibility in Chinese Uygur Population: A Case-Control study.

Authors:  Li Wang; Wenhui Zhao; Jiajing Hong; Fanglin Niu; Jing Li; Shanshan Zhang; Tianbo Jin
Journal:  Mol Genet Genomic Med       Date:  2019-06-20       Impact factor: 2.183

7.  Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy.

Authors:  Cristina Buigues; Rut Navarro-Martínez; Vanessa Sánchez-Martínez; María Serrano-Carrascosa; José Rubio-Briones; Omar Cauli
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

8.  Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China.

Authors:  Shun Xu; Yongtao Hu; Ligang Zhang; Shaoyu Yue; Li Zhang; Chaozhao Liang
Journal:  Contrast Media Mol Imaging       Date:  2022-08-13       Impact factor: 3.009

Review 9.  Interleukin-1 Beta-A Friend or Foe in Malignancies?

Authors:  Rebekka Bent; Lorna Moll; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.